Exicure’s Program for Friedreich’s Ataxia Not Altered by COVID-19

Print Friendly, PDF & Email

The COVID-19 pandemic has not affected the preclinical program of XCUR-FXN , an experimental treatment for Friedreich’s ataxia (FA), Illinois-based Exicure said. Since biotechnology companies were designated essential businesses by the state’s governor J.B. Pritzker, Exicure will continue its research programs despite the the “stay-at-home” order in Illinois. The […]